Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Steroidogenesis Inhibitors (STGI) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Burnham who wrote (130)	9/7/1999 3:32:00 PM
From: Jim Burnham	Read Replies (2) \| Respond to of 294

STEROIDOGENESIS INHIBITORS INTERNATIONAL INC - Forms Strategic Alliance with Cato Research, Ltd. [219] Steroidogenesis Inhibitors International, Inc, through its recent affiliation with Pashua Partners, L.P., has announced the engagement of Cato Research, Ltd. to implement a long-range clinical and business development plan to facilitate FDA approval and manufacturing of ANTICORT(TM) worldwide. Cato Research, Ltd. is an independent contract research and development company that plans, implements and analyzes clinical studies and facilitates the FDA approval of new drug entities. The company also participates in the development of regulatory strategy for drugs and biologics, supervises the preparation of FDA meeting submission packages, and attends FDA meetings on behalf of clients. Cato Research is headquartered near Research Triangle in North Carolina, with additional offices located in Washington D.C., San Francisco, Montreal, Canada, and Tel Aviv, Israel. The company employs over 200 persons worldwide. Dr. Alfred T. Sapse, President of Steroidogenesis Inhibitors International, Inc. states: "We are very pleased to have the talent and experience of the Cato Research team allied with us as we further our goals of bringing ANTICORT(TM) to the market. The extensive efforts already put forth by Cato Research over the past several months in developing our future clinical and business plan for STGI are most impressive. We truly believe that this creates a dynamic strategic alliance that will accelerate material results for our continued success." STGI is a pharmaceutical company engaged in the field of developing anti-cortisol drugs intended for the treatment of diseases associated with elevated levels of cortisol, aging and Alzheimer's included. This release may include "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com. TEL: (702) 221-0409 Steroidogenesis, Janet Greeson Ph.D. TEL: (303) 948-3601 Performance Strategies, Inc. Richard L. Brown/Charles E. (Chuck) Jordan, Sr.